Race Oncology Ltd has released a press release.
Issue of Options
Filed with ASX ·
On 6ix: 6ix.com/news/issue-of-options-67
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Peer-Reviewed The Rediscovery of Bisantrene Published
- Race Completes Over-Subscribed $2.5 Million Placement
- Race Joint Venture with TargImmune
- Race Announces NCI Collaboration
- Bisantrene License Agreement for Korea
Later from Racura Oncology
- Appendix 4E & Annual Financial Statements
- Race Oncology Produces First Batch of Bisantrene
- Race Receives $170k R&D Tax Incentive Refund
- Notice of Allowance for Bisantrene Patent in US
- Second Bisantrene Patent Allowed in US
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology